Coral Springs, FLORIDA, March 16, 2015 /PRNewswire/ --
The global market for fish oil omega-3 is projected to grow from $1.1 billion in 2011 to $1.7 billion by 2018. Globally rising awareness about the importance of omega-3 fatty acids - of which fish oil is a primary source - for several purposes in the human body, is an important driver of the global market for fish oil. Nutrition & Supplement Companies in focus today are: Axxess Pharma Inc. (OTC: AXXE), MusclePharm Corporation (OTC: MSLP), GNC Holdings, Inc. (NYSE: GNC), Herbalife Ltd. (NYSE: HLF) and Amarin Corporation Plc (NASDAQ: AMRN).
Axxess Pharma Inc. (OTC: AXXE) a specialty pharmaceutical and nutritional supplements company, through its wholly owned subsidiary, AllStar Health Brands Inc., is pleased to announce they have now received FDA approval from the United States to sell their high potency Omega-3 fish oil, Muscle Growth, Muscle Recovery supplements and Turbo Blend Protein Powders. The recent FDA approval comes less than two weeks after Axxess Pharma's successful meetings with two of the United States largest distributors.
Read the full AXXE Press Release at http://www.financialnewsmedia.com/profiles/axxe.html
Axxess's FDA approval will not only allow this new line of products to be distributed nationally into big box retail chain stores, but will also facilitate entry into more regulated markets such as Mexico and other foreign jurisdictions. Axxess expects the latest FDA approval to accelerate the pace of current overseas sales. Management is now projecting, year over year sales from March 2015 to March 2016 of $2.5 million. Dr. Daniel Bagi, President of Axxess Pharma, Inc. stated "We are very excited to receive FDA approval to sell our latest line of all-natural TapouT supplements and protein powders within the US. Our all-natural products will be sold under the globally recognized name TapouT, and will have the words 'FDA Approved' on every label. Our unique high potency Omega-3 fish oil supplements is anticipated to be one of our top sellers both in the US and internationally."
In other nutrition & supplement news & happenings: MusclePharm Corporation (OTCQB: MSLP), a scientifically driven, performance-lifestyle sports nutrition company, recently announced it has entered into a strategic manufacturing agreement with an option to purchase Capstone Nutrition, one of the largest pure-play developers and manufacturers in the nutrition industry. Under the terms of the agreement, MusclePharm will consolidate all of its domestic powder, capsule and tablet manufacturing into applicable Capstone facilities. In connection with the consolidation, MusclePharm will receive warrants equal to 19.9 percent of Capstone, as well as the right to purchase the remaining 80.1 percent of Capstone during the next 18 months. In addition, MusclePharm is contributing $2.5 million to the build out of Capstone's manufacturing facilities to meet MusclePharm's manufacturing requirements.
GNC Holdings, Inc. (NYSE: GNC), a leading global specialty retailer of health and wellness products, last week announced that independent, third party testing of certain product lots in its Herbal Plus® product line has confirmed that the products are safe, pure, properly labeled and in full compliance with all regulatory requirements. Michael G. Archbold, Chief Executive Officer of GNC said, "This additional round of tests leaves no doubt that our products are not only pure but are in full compliance with all regulatory requirements.
Herbalife Ltd. (NYSE: HLF), a global nutrition company, joined with its members around the world this weekend to create a new GUINNESS WORLD RECORDS® achievement for most participants in a High Intensity Interval Training (HIIT) workout in 24-hours. As part of the event, Herbalife and its members also created a new world record for number of people in a High Intensity Interval Training Workout in one location, with nearly 4,000 people filling the LA Live Plaza in Downtown Los Angeles.
Amarin Corporation Plc (NASDAQ: AMRN), announced recently the presentation of findings from a new in vitrostudy that the combination of eicosapentaenoic acid (EPA), an omega-3 fatty acid, and the active metabolite of atorvastatin (ATM) provided significantly increased nitric oxide (NO) bioavailability in an additive fashion. The study found that this effect was not observed with other triglyceride lowering agents (fenofibrate, niacin, or gemfibrozil) or the omega-3 fatty acid docosahexaenoic acid (DHA). The research was presented yesterday at a peer-reviewed poster session at the DEUEL Conference on Lipids in Monterey, California.
FinancialNewsMedia.com is leading provider of third party publishing & news dissemination services. If you would like more information regarding our news coverage solutions, please visit http://www.financialnewsmedia.com for more details. Get an edge on the market with our Premium News Alerts that are FREE for a limited time at http://www.financialnewsmedia.com/. Follow us on Facebook: http://www.facebook.com/financialnewsmedia and Twitter: http://twitter.com/FNMgroup.
DISCLAIMER: FN Media Group LLC (FNMG) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNMG is NOT affiliated in any manner with any company mentioned herein. FNMG and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNMG's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. FNMG is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed FNMG has been compensated one thousand four hundred dollars for news coverage of the current press release issued by AXXE by the company. FNMG HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements.
SOURCE FN Media Group, LLC